Treatment efficacy and methotrexate-related toxicity in patients with rheumatoid arthritis receiving methotrexate in combination with adalimumab

Burmester, Gerd R; Kaeley, Gurjit S; Kavanaugh, Arthur F; Gabay, Cem; MacCarter, Daryl K; Nash, Peter; Takeuchi, Tsutomu; Goss, Sandra L; Rodila, Ramona; Chen, Kun; Kupper, Hartmut; Kalabic, Jasmina

doi:10.1136/rmdopen-2017-000465

Scientific article

English

Treatment efficacy and methotrexate-related toxicity in patients with rheumatoid arthritis receiving methotrexate in combination with adalimumab

ContributorsBurmester, Gerd R; Kaeley, Gurjit S; Kavanaugh, Arthur F; Gabay, Cem; MacCarter, Daryl K; Nash, Peter; Takeuchi, Tsutomu; Goss, Sandra L; Rodila, Ramona; Chen, Kun; Kupper, Hartmut; Kalabic, Jasmina

Published inRMD Open, vol. 3, no. 2, e000465

Publication date2017

Abstract

Treatment of rheumatoid arthritis (RA) with a combination of methotrexate (MTX)+adalimumab (ADA) is more effective than ADA monotherapy. We assessed the toxicity of different doses of MTX and treatment efficacy of ADA+MTX in two trials.

Affiliation entities

Faculté de médecine / Section de médecine clinique / Département de médecine

Research groups

Inflammation articulaire (44)

Citation (ISO format)

BURMESTER, Gerd R et al. Treatment efficacy and methotrexate-related toxicity in patients with rheumatoid arthritis receiving methotrexate in combination with adalimumab. In: RMD Open, 2017, vol. 3, n° 2, p. e000465. doi: 10.1136/rmdopen-2017-000465

Article (Published version)

CC BY-NC

Identifiers

PID : unige:110660
DOI : 10.1136/rmdopen-2017-000465
PMID : 28955494

Journal ISSN2056-5933

397views

357downloads

Creation03/09/2018 11:18:00

First validation03/09/2018 11:18:00

Update24/01/2025 14:27:57

Status update24/01/2025 14:27:57

Last indexation24/01/2025 14:36:22

Archive ouverte UNIGE

Treatment efficacy and methotrexate-related toxicity in patients with rheumatoid arthritis receiving methotrexate in combination with adalimumab

Treatment of rheumatoid arthritis (RA) with a combination of methotrexate (MTX)+adalimumab (ADA) is more effective than ADA monotherapy. We assessed the toxicity of different doses of MTX and treatment efficacy of ADA+MTX in two trials.

Technical informations